Anika Therapeutics (ANIK) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings or view top-rated stocks.

2 brokers have issued 12-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $28.00 to $31.00. On average, they anticipate the company's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.

Anika Therapeutics' stock was trading at $29.60 at the start of the year. Since then, ANIK stock has decreased by 7.5% and is now trading at $27.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our ANIK earnings forecast.

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Monday, March, 6th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biotechnology company had revenue of $39.62 million for the quarter, compared to analysts' expectations of $38.32 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 3.77% and a negative net margin of 14.15%.

ETFs with the largest weight of Anika Therapeutics (NASDAQ:ANIK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Royce Quant Small-Cap Quality Value ETF (SQLV), Syntax Stratified SmallCap ETF (SSLY), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Vanguard U.S. Minimum Volatility ETF (VFMV) and

Anika Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $161.06 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.67%), Trigran Investments Inc. (10.85%), Dimensional Fund Advisors LP (6.64%), State Street Corp (6.23%), Caligan Partners LP (4.85%) and Renaissance Technologies LLC (3.90%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIK stock can currently be purchased for approximately $27.37.

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $403.98 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

The company employs 297 workers across the globe.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.